Gilead’s biannual HIV shot reduced risk of infections by 96 percent, company says
Drugmaker Gilead Science announced Thursday that its biannual injections to prevent against HIV had slashed the risk of ...
Objections on Gilead’s HIV drug patent claims to be heard
Gilead has several patent applications in India on lenacapavir. Two of these patent applications, filed in 2020, seek patents ...
Gilead Sciences stock nears its all-time high: buy or sell?
Gilead Sciences (GILD) stock price has staged a strong comeback this year, helped by strong earnings and a recent $40 million ...
GlobalData on MSN3d
Gilead’s lenacapavir: HIV prospects strongest in long-acting combos with Merck’s islatravir
Gilead Sciences’ capsid inhibitor lenacapavir has the most competitive potential in long-acting combination regimens in HIV, ...
Indian Patent Office to hear objections on Gilead's HIV drug patent claims
On September 19, 2024, the Indian Patent Office will hear objections filed by Sankalp Rehabilitation Trust against Gilead's ...
Activists sound alarm bells as Gilead seeks rights over HIV drug
Lenacapavir, a very expensive drug, is not available in India and many other countries. If the Indian Patent Office clears ...
BioSpace6d
Gilead Touts 96% HIV Risk Reduction With Twice-Yearly PrEP, Eyes Regulatory Filings
Armed with readouts from the PURPOSE 1 and 2 trials, Gilead Sciences is now gearing up for global regulatory submissions for ...
Health activists object to patent filed by US firm Gilead Sciences on anti-HIV drug
The Mumbai-based non-government entity called Sankalp Rehabilitation Trust, which works with HIV-positive people, had opposed ...
Patent opposition case against Gilead’s long-acting HIV injectable drug, comes up this week
The US-based Gilead Sciences’ long-acting injectable HIV drug lenacapavir is at the centre of a patent opposition case ...
Buy Rating on Gilead Sciences: Underestimated Market Potential of Lenacapavir in HIV Treatment and Prevention
J.P. Morgan analyst Chris Schott has maintained their bullish stance on GILD stock, giving a Buy rating on September 13. Chris Schott has ...
Yahoo Finance3d
Gilead’s lenacapavir: HIV prospects strongest in long-acting combos with Merck’s islatravir
Gilead Sciences’ capsid inhibitor lenacapavir has the most competitive potential in long-acting combination regimens in HIV, including with Merck’s islatravir, experts said. Early lenacapavir ...
infectiousdiseaseadvisor.com2d
Twice-Yearly Injection Reduces HIV Risk by 96%, But Will Cost Cut Access?
It could be a real breakthrough for people at risk for HIV infection: A shot given every 6 months that reduces their risk by a whopping 96%.